DEF 14A: Tandem Diabetes Care Seeks Stockholder Approval for Amended Equity Plans

Tandem Diabetes Care is asking stockholders to approve amendments to its 2013 Employee Stock Purchase Plan and 2023 Long-Term Incentive Plan to increase the number of shares available for issuance.

Summary

• Tandem Diabetes Care is holding its 2024 Annual Meeting of Stockholders on May 22, 2024, virtually.
• The company is seeking stockholder approval to elect nine directors, approve amendments to the 2013 Employee Stock Purchase Plan (ESPP) and the 2023 Long-Term Incentive Plan (LTIP), provide an advisory vote on executive compensation, and ratify the appointment of Ernst & Young LLP as its independent auditor.
• The proposed amendment to the 2013 ESPP would increase the number of shares available for issuance by 3,000,000 shares.
• The proposed amendment to the 2023 LTIP would also increase the number of shares available for issuance by 3,000,000 shares, bringing the total to 5,602,184 shares.
• The board of directors recommends voting in favor of all proposals.
• In 2023, Tandem Diabetes Care achieved worldwide sales of approximately $750 million and increased its worldwide customer base by about 7%.

Sentiment

Score: 6

Explanation: The document is neutral. While there are positive aspects like sales growth and customer retention, there are also negative aspects like not meeting company goals and the impact of market dynamics.

Positives

• The company is committed to reinforcing ethical governance and maintaining operational excellence.
• Tandem Diabetes Care is focused on improving the lives of people with diabetes through innovation and customer experience.
• The company has a strong commitment to environmental, social, and governance (ESG) priorities.
• The company has a clawback policy in place for executive compensation.
• The company has stock ownership guidelines for executive officers and directors.

Negatives

• Kim Blickenstaff will not be standing for reelection at the 2024 annual meeting of stockholders.
• The company did not meet its 2023 company goals in their entirety and NEOs did not earn their targeted compensation for the year.

Risks

• The outcomes of forward-looking statements are subject to risks, uncertainties, and other factors described in the company's Annual Report.
• The company faces risks relating to its business, operations, strategic direction, regulatory environment, legal matters, financial stability, compliance, liability, information technology, human capital management, compensation, cybersecurity, environmental issues, social concerns, governance practices, and reputational risks.

Future Outlook

The company estimates that the shares authorized for issuance under the 2013 ESPP following the amendment would be sufficient to continue to make offerings for approximately three years, while the shares authorized for issuance under the 2023 Plan would be sufficient to grant awards for at least one year.

Management Comments

• The company delivered historical highs in customer renewals and strong retention of in-warranty customers, demonstrating high satisfaction with the technology.
• The company increased its worldwide customer base to new levels, exiting the year with more than 450,000 in-warranty customers.
• The company focused on building and preparing for the future as it executed on multiple strategic initiatives.

Industry Context

The company operates in a highly competitive environment within the medical device and technology industries, particularly in the diabetes care sector.

Comparison to Industry Standards

• The company benchmarks its executive compensation to just above market at the 60th percentile compared to relevant survey data.
• The company's peer group includes Abiomed, Dexcom, Insulet, and other similar companies in the healthcare equipment and services industries.
• The company's annual burn rate has been 3.5% or less over the past 3 years, with an average of 2.4% for fiscal year 2023.

Management Changes

Corporate Governance

Related Party Transactions

• Mr. Sheridan, our President and Chief Executive Officer and a member of our board of directors, and Ms. Vosseller, our Executive Vice President, Chief Financial Officer and Treasurer, are involved in a personal relationship and share a primary residence.
• Mr. Twomey, a member of our board of directors, is the brother-in-law of one of our employees who is a manufacturing engineer.

Stakeholder Impact

• Approval of the equity plans is intended to motivate and incentivize employees and directors, aligning their interests with those of stockholders.
• The company's commitment to ESG priorities aims to create a safe and inclusive work environment and foster diversity.
• The company's focus on innovation and customer experience is intended to improve the lives of people with diabetes.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will publish final voting results in a Current Report on Form 8-K within four business days following the Annual Meeting.

Key Dates

Keywords

Tandem Diabetes Care, proxy statement, annual meeting, stockholders, directors, executive compensation, employee stock purchase plan, long-term incentive plan, governance, audit, equity, shares